MRI for chronic liver diseases

The term "chronic liver diseases" covers a large number of different diseases, most of which are metabolic (fatty liver disease, haemochromatosis) or infectious (hepatitis B, C) in origin and are associated with diffuse alteration of the liver parenchyma.

MRI for fatty liver cells/steatosis

Liver steatosis is a reversible storage of fat droplets (mainly triglycerides) in the liver cells. A distinction is made etiologically between the much more common alcohol-induced fatty liver disease (ALD) and non-alcoholic fatty liver disease (NAFLD). An important subtype of NAFLD is non-alcohol-induced steato-hepatitis (NASH), which is characterized by diffuse fatty degeneration of the liver and an additional inflammatory reaction (1).

Magnetic resonance imaging is the best method for determining liver fat content. In addition to the visual, qualitative assessment, MRI also enables a quantitative assessment of fatty liver. The quantification of fat in MRI is made possible by measuring the signal intensity ratio of the fat signal to the absolute signal in terms of a fat signal fraction (FSF). Using this technique, MRI can reliably distinguish between healthy and steatotic livers and identify patients at risk of liver surgery.

MRI for hemochromatosis

Haemochromatosis is a hereditary disease with increased iron absorption in the upper small intestine. This leads to iron deposition, particularly in the liver, pancreas, lymph nodes, heart and skin. Secondary haemochromatosis or haemosiderosis must be distinguished from primary haemochromatosis, which is an acquired iron overload of the liver. Due to an increased iron intake/release, e.g. in the context of blood transfusions or chronic hemolysis, iron deposits primarily occur in the liver and spleen.

In addition to liver fat determination, magnetic resonance imaging is also the best non-invasive method for determining the liver iron content in the context of hemochromatosis. In addition to the visual assessment, a quantitative assessment of iron overload is also possible with MRI. Based on the iron load determined in the MRI, either the diagnosis can be made, treatment can be initiated if necessary or treatment that has already been started can be monitored.

Magnetic resonance elastography for liver fibrosis/cirrhosis

Fibrosis is generally understood to be a proliferation of connective tissue in the liver tissue as a reaction to cell damage, usually in the context of liver inflammation(hepatitis). The increase in the extracellular matrix leads to a loss of liver function and, secondarily, to portal hypertension with complications such as esophageal varices, ascites or even liver failure. The development of liver fibrosis is related to the duration and intensity of exposure to the noxious agent and is reversible in the early stages. The final stage of diffuse liver fibrosis is liver cirrhosis.

The measurement of liver stiffness using ultrasound and magnetic resonance elastography has proven to be a promising indicator of the degree of fibrosis. In magnetic resonance elastography, pressure waves are generated via an external vibration device on the upper abdomen, which cyclically compress the adjacent liver. Using a special sequence, it is possible to visualize the progression of the waves or their wavelength and thus draw conclusions about liver stiffness or the individual stages of fibrosis.

  1. Farrell GC, Larter CZ. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology. 2006;43(2 Suppl 1):S99-S112.
  2. Meisamy S, Hines CD, Hamilton G, et al. Quantification of hepatic steatosis with T1-independent, T2-corrected MR imaging with spectral modeling of fat: blinded comparison with MR spectroscopy. Radiology. 2011;258(3):767-75.
  3. Pietrangelo A. Hereditary hemochromatosis: pathogenesis, diagnosis, and treatment. Gastroenterology. 2010;139(2):393-408, e1-2.
  4. Gandon Y, Olivie D, Guyader D, et al. Non-invasive assessment of hepatic iron stores by MRI. Lancet. 2004;363(9406):357-62.
  5. Faria SC, Ganesan K, Mwangi I, et al. MR imaging of liver fibrosis: current state of the art. Radiographics. 2009;29(6):1615-35.

Responsible doctors

Andreas Hötker, PD Dr. med.

Senior Physician, Institute for Diagnostic and Interventional Radiology

Tel. +41 43 253 85 12
Specialties: Urogenital radiology, Gastrointestinal radiology, Magnetic resonance imaging

Soleen Stocker, Dr. med.

Senior Attending Physician, Institute for Diagnostic and Interventional Radiology

Tel. +41 44 253 11 67
Specialties: Urogenital and gynecological imaging, Abdominal imaging, Oncological imaging

Daniel Stocker, Dr. med.

Attending Physician, Institute for Diagnostic and Interventional Radiology

Tel. +41 43 253 25 99

For patients

As a patient, you cannot register directly for a consultation. Please get a referral from your primary care physician, specialist.

For referrer

University Hospital Zurich
Institute for Diagnostic and Interventional Radiology
Raemistrasse 100
8091 Zurich

Tel. +41 43 254 41 10
Assign online